Clinical trials: Depressive; Behavioral Disorder
Depression
E-Mental Health Adolescent Depression Program (LEAP)
The purpose of this project is to explore the potential value and practicality of an innovative depression intervention for young people. More specifically, the objectives of this project are: 1.
- Trial name
- LEAP (NCT00985686)
- Testing
- LEAP Project
- Where
- Canada
- Volunteers
- 63 people
- Sponsor
- Patricia Steele
Major Depressive Disorder
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
One-third or more of individuals treated for major depressive disorder (MDD) do not experience remission of symptoms despite at least two adequate antidepressant trials.
- Trial name
- PAGE-1_AG1 (NCT01426516)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Genomind, LLC
Health Attitude, Knowledge, Attitudes, Practice
Postnatal mHealth Intervention Development
This study is a six-week exploratory developmental phase (phase 1) of a larger project to develop an mHealth intervention targeting health education and social support for Indian women in the postnatal period.
- Conditions
- Health Attitude, Knowledge, Attitudes, Practice, Postpartum Depression, Acceptability of Health Care
- Trial name
- MESSAGE (NCT04636398)
- Testing
- MESSAGE - mHealth intervention
- Where
- India
- Volunteers
- 29 people
- Sponsor
- University of California, San Francisco
Major Depressive Disorder, Treatment-Resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly.
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Depression
- Trial name
- NCT04821271
- Testing
- TS-161
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111552
- Testing
- Escitalopram, Aripiprazole
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 237 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression, Major Depressive Disorder
A Trial of AXS-05 in Patients With Major Depressive Disorder
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).
- Trial name
- GEMINI (NCT04019704)
- Testing
- AXS-05
- Where
- 43 sites in United States
- Volunteers
- 327 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder
Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression
The long-term goal of this line of research is to determine if decreased vascular reactivity and frontal hypoperfusion is associated with poor response antidepressants.
- Trial name
- NCT01896934
- Testing
- Sertraline
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vanderbilt University
Depressive Disorder, Major
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01153009
- Testing
- Vortioxetine, Duloxetine
- Where
- 56 sites in United States
- Volunteers
- 614 people
- Sponsor
- Takeda
Depressive Disorder
Integrating a Stepped Care Model of Screening and Treatment for Depression Into Malawi's National HIV Care Delivery Platform
Malawi is a low-income country in sub-Saharan Africa that has limited resources to address a significant burden of disease-including HIV/AIDS.
- Trial name
- IC3D (NCT04777006)
- Testing
- Problem Management Plus, Antidepressant Therapy
- Where
- Malawi
- Volunteers
- 487 people
- Sponsor
- RAND
Major Depressive Disorder, Generalized Anxiety Disorder
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
The primary objective of the study is to determine whether quetiapine extended-release in combination with cognitive behavioral therapy (CBT) is more effective than CBT plus placebo in treating depressive and anxiety symptoms in…
- Trial name
- NCT01971203
- Testing
- seroquel xr, CBT
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Disorder
Brain GABA Levels and Treatment Response in Major Depressive Disorder
This study will evaluate changes in brain gamma-aminobutyric acid (GABA) levels due to treatment with escitalopram in people with major depressive disorder.
- Trial name
- NCT00464711
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Anxiety, Depressive Symptoms
Stepped-Care Telehealth for Distress in Cancer Survivors
Mental health issues in post-treatment adult cancer survivors are associated with multiple adverse outcomes and may represent a cancer health disparity for rural survivors.
- Conditions
- Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease
- Trial name
- Telehealth (NCT03060096)
- Testing
- Severe Anxiety/depression: High Intensity Stepped Care, Moderate Anxiety/depression: Low Intensity Stepped care, Enhanced Usual Care Control
- Where
- 166 sites in United States
- Volunteers
- 68 people
- Sponsor
- Wake Forest University Health Sciences
Major Depressive Disorder, MDD
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken for 52 weeks with another antidepressant…
- Conditions
- Major Depressive Disorder, MDD, Depression
- Trial name
- NCT01152554
- Testing
- TC-5214
- Where
- 94 sites in United States, Puerto Rico
- Volunteers
- 813 people
- Sponsor
- AstraZeneca
Childhood Traumatic Grief, Post Traumatic Stress
Randomized Controlled Trial of Trauma-focused CBT in Tanzania and Kenya
The primary goal is to study the effectiveness of Trauma-focused Cognitive Behavioral Therapy (TF-CBT) in treating traumatic grief and traumatic stress for orphaned children and young adolescents in two East African sites with…
- Conditions
- Childhood Traumatic Grief, Post Traumatic Stress, Post Traumatic Stress Disorder, Depressive Symptoms
- Trial name
- NCT01822366
- Testing
- Trauma-focused Cognitive Behavioral Therapy
- Where
- 3 sites in United States, Kenya and 1 more
- Volunteers
- 1,280 people
- Sponsor
- Duke University
Nicotine Dependence, Major Depressive Disorder
Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
Persons who struggle with depression smoke at high rates and experience low quit rates in treatment. The best way to improve cessation treatment for this underserved population remains unknown.
- Trial name
- NCT02378714
- Testing
- Varenicline, BASC, Standard treatment
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Northwestern University
Perinatal Depression, Postpartum Depression
Development, Feasibility and Acceptability of Fathers and Babies (FAB): A Pilot Study
During this project the investigators will develop and pilot test a companion intervention for fathers (Fathers and Babies-FAB), to supplement the Mothers and Babies Course (MB) that provides stress and mood management tools for…
- Conditions
- Perinatal Depression, Postpartum Depression, Depression
- Trial name
- NCT03427528
- Testing
- Fathers and Babies (FAB), MB 1-on-1 plus TXT
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Depression, Mood Disorders
Rapid Antidepressant Effects of Ketamine in Major Depression
Depressive disorders may be severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses.
- Conditions
- Depression, Mood Disorders, Major Depresssion
- Trial name
- NCT00088699
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
AZD7268 Safety and Tolerability Study
The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
- Trial name
- NCT01020799
- Testing
- AZD7268, Escitalopram
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- AstraZeneca
Treatment Resistant Depression, Major Depressive Disorder
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression
In this proof of concept study, the investigators plan to administer iv ketamine interleaved with ECT days. Patients with treatment resistant depression who are deemed to be eligible for ECT treatment will randomly be assigned to…
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
- Trial name
- NCT02522377
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Cleveland Clinic
Depressive Disorder
Depressed Mood Improvement Through Nicotine Dosing 2
Deficits in cognitive control are core features of late-life depression, contributing both to emotion dysregulation and problems with inhibiting irrelevant information, conflict detection, and working memory.
- Trial name
- DepMIND2 (NCT04433767)
- Testing
- Transdermal Nicotine patch
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Vanderbilt University Medical Center